These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea. Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276 [TBL] [Abstract][Full Text] [Related]
44. Management of drug resistantTB in patients with HIV co-infection. Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945 [TBL] [Abstract][Full Text] [Related]
45. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis. Mikiashvili L; Kempker RR; Chakhaia TS; Bablishvili N; Avaliani Z; Lomtadze N; Schechter MC; Kipiani M Clin Infect Dis; 2024 Apr; 78(4):1043-1052. PubMed ID: 37962987 [TBL] [Abstract][Full Text] [Related]
46. Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent. Luo W; Huang Z; Xu D; Yang M; Zhu Y; Shen L; Chen S; Tao X; Bin W; Hu Y; Franzblau SG; Jiang N; Wei Y; Wei X; Ding CZ Bioorg Med Chem Lett; 2022 Sep; 72():128871. PubMed ID: 35777718 [TBL] [Abstract][Full Text] [Related]
47. [Clinical analysis of adverse reactions in patients with multidrug-resistant and rifampicin-resistant pulmonary tuberculosis treated with delamanid-containing regimen]. Gao MQ; Gao JT; Ma XG; Shu W; Du J; Liang RX; Wu GH; Pei Y; Yan XF; Cai QS; Lyu KY; Cai C; Wu YQ; Li XJ; Liu QQ; Jin L; Wu QH; Xiong Y; Li MW; Zhou YQ; Kuang HB; Wang XF; Ren F; Chen XH; Geng SJ; Zhou Y; Sha W; Yang GL; Wang H; Zhan Y; Liu YH; Li L Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jul; 47(7):638-646. PubMed ID: 38955749 [No Abstract] [Full Text] [Related]
48. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging. Li Y; Sun F; Zhang W Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290 [TBL] [Abstract][Full Text] [Related]
49. Effect of Bedaquiline and Delamanid Pharmacokinetics on Sputum Culture Conversion and Adverse Events in Drug-Resistant Tuberculosis. Bhatnagar AK; Hemanthkumar AK; Muthu Vijayalakshmi M; Vohra V; Padmapriyadarsini C; Ramesh PM; Taneja G; Chavan VN; Jeyadeepa B; Bhui NK; Solanki R Ther Drug Monit; 2024 Jun; 46(3):363-369. PubMed ID: 38161267 [TBL] [Abstract][Full Text] [Related]
50. Synthetic investigational new drugs for the treatment of tuberculosis. Kwon YS; Koh WJ Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631 [TBL] [Abstract][Full Text] [Related]
52. The Activities and Secretion of Cytokines Caused by Delamanid on Macrophages Infected by Multidrug-Resistant Lyu XL; Lin TT; Gao JT; Jia HY; Zhu CZ; Li ZH; Dong J; Sun Q; Shu W; Pan LP; Zhang ZD; Li Q Front Immunol; 2021; 12():796677. PubMed ID: 35003120 [TBL] [Abstract][Full Text] [Related]
53. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Diacon AH; Dawson R; Hanekom M; Narunsky K; Venter A; Hittel N; Geiter LJ; Wells CD; Paccaly AJ; Donald PR Int J Tuberc Lung Dis; 2011 Jul; 15(7):949-54. PubMed ID: 21682970 [TBL] [Abstract][Full Text] [Related]
55. Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis. Maretbayeva SM; Rakisheva AS; Adenov MM; Yeraliyeva LT; Algozhin YZ; Stambekova AT; Berikova EA; Yedilbayev A; Rich ML; Seung KJ; Issayeva AM Int J Infect Dis; 2021 Dec; 113 Suppl 1():S91-S95. PubMed ID: 33823277 [TBL] [Abstract][Full Text] [Related]
56. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. Yoon HY; Jo KW; Nam GB; Shim TS Int J Tuberc Lung Dis; 2017 Sep; 21(9):996-1001. PubMed ID: 28826448 [TBL] [Abstract][Full Text] [Related]
57. Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis. Putra ON; Yulistiani Y; Soedarsono S Int J Mycobacteriol; 2022; 11(4):349-355. PubMed ID: 36510917 [TBL] [Abstract][Full Text] [Related]
58. Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis. Cox V; Brigden G; Crespo RH; Lessem E; Lynch S; Rich ML; Waning B; Furin J Int J Tuberc Lung Dis; 2018 Apr; 22(4):407-412. PubMed ID: 29562988 [TBL] [Abstract][Full Text] [Related]
59. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. Centers for Disease Control and Prevention MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696 [TBL] [Abstract][Full Text] [Related]
60. Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- and Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. Holmgaard FB; Guglielmetti L; Lillebaek T; Andersen ÅB; Wejse C; Dahl VN Clin Infect Dis; 2023 Apr; 76(7):1328-1337. PubMed ID: 36331978 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]